(Q34609407)

3 August 2017

1 reference

title

Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? (English)

1 reference

3 August 2017

0 references

Arnott ID

1

1 reference

3 August 2017

Watts D

series ordinal

2

1 reference

3 August 2017

Ghosh S

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

Alimentary Pharmacology & Therapeutics

3 August 2017

1 reference

3 August 2017

16

1 reference

3 August 2017

5

1 reference

3 August 2017

857-867

1 reference

Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983; marginal fall in ulcerative colitis, three-fold rise in Crohn's disease

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Cardiff Crohn's disease jubilee: the incidence over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Disease activity courses in a regional cohort of Crohn's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Short-term course and prognosis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Effects of cigarette smoking on the long-term course of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Scanning electron-microscopic lesions in Crohn's disease: relevance for the interpretation of postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Preventing postoperative recurrence of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Recurrence of Crohn's disease after resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Reoperation and recurrence in Crohn's colitis and ileocolitis Crude and cumulative rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Factors influencing postoperative recurrence of Crohn's disease in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Postoperative outcome of Crohn's disease in 30 children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01242.X

10.1046/J.1365-2036.2002.01242.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference